Abstract
Recently, the use of oncolytic viruses against cancer has attracted considerable attention. We studied the potential of the US3 locus-deficient herpes simplex virus (HSV), L1BR1, for oncolytic virus therapy. Its high specificity and potency indicate that L1BR1 is a promising candidate as a new oncolytic virus against pancreatic cancer. Moreover, the virus exhibited the unique characteristic of increasing apoptosis when used in combination with anticancer drugs. We assessed the feasibility of using the US3 locus-deficient HSV named L1BR1 as a new replication-competent oncolytic virus for the treatment of pancreatic cancer. The US3 locus of HSV has been shown to be a key gene in producing a multifunctional protein kinase that inhibits apoptosis induced by viral infections, chemicals and ultraviolet (UV) light. L1BR1 has been reported to be more than 10 000-fold less virulent than the parental virus in mice. In this study, we examined the tumor specificity and oncolytic effect of this attenuated replication-competent virus, L1BR1, in pancreatic cancers derived from SW1990, Capan2 and Bxpc-3cells compared with the parent virus and other well-known oncolytic herpes viruses (R3616 and hrR3). We also studied the efficacy of L1BR1 for the induction of apoptosis as an attribute of this virus in combination with the anticancer drugs 5FU and cisplatin. The combined treatment of the pancreatic cancer cells with L1BR1 and these anticancer drugs enhanced apoptosis significantly. More importantly, L1BR1 showed the lowest replication capacity in normal human hepatocytes, but the highest tumor-reducing effect in vivo among the oncolytic herpes viruses tested. In addition, L1BR1 significantly increased the induction of apoptosis of cancer cells when treated in combination with anticancer drugs although the parental virus inhibited the induction of apoptosis. These results suggest that L1BR1 is promising as a new anticancer oncolytic virus.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
O'Brien V . Virus and apoptosis. J Gen Virol 1998; 66: 6939–6945.
Teodoro JG, Branton PE . Regulation of p53-dependent apoptosis, transcriptional repression, and cell transformation by phosphorylation of the 55-kilodalton E1B protein of human adenovirus type 5. J Virol 1997; 71: 3620–3627.
Teodoro JG, Branton PE . Regulation of apoptosis by viral gene products. J Virol 1997; 71: 1739–1746.
Tschopp J, Thome M, Hofmann K, Meinl E . The fight of viruses against apoptosis. Curr Opin Genet Dev 1998; 8: 82–87.
Nishiyama Y, Murata T . Anti-apoptotic protein kinase of herpes simplex virus. Trends Microbiol 2002; 10: 105–107.
Murata T, Goshima F, Daikoku T, Takakuwa H, Nishiyama Y . Expression of herpes simplex virus type 2 US3 affects the Cdc42/Rac pathway and attenuates c-Jun N-terminal kinase activation. Genes Cells 2000; 5: 1017–1027.
Leopardi R, Van Sant C, Roizman B . The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus. Proc Natl Acad Sci USA 1997; 94: 7891–7896.
Munger J, Roizman B . The US3 protein kinase of herpes simplex virus 1 mediates the posttranslational modification of BAD and prevents BAD-induced programmed cell death in the absence of other viral proteins. Proc Natl Acad Sci USA 2001; 98: 10410–10415.
Nishiyama Y, Yamada Y, Kurachi R, Daikoku T . Construction of a US3 lacZ insertion mutant of herpes simplex virus type 2 and characterization of its phenotype in vitro and in vivo. Virology 1992; 190: 256–268.
Asano S, Honda T, Goshima F . US3 protein kinase of herpes simplex virus type 2 plays a role in protecting corneal epithelial cells from apoptosis in infected mice. J Gen Virol 1999; 80: 51–56.
Aubert M, Blaho JA . The herpes simplex virus type 1 regulatory protein ICP27 is required for the prevention of apoptosis in infected human cells. J Virol 1999; 73: 2803–2813.
Galvan V, Roizman B . Herpes simplex virus 1 induces and blocks apoptosis at multiple steps during infection and protects cells from exogenous inducers in a cell-type-dependent manner. Proc Natl Acad Sci USA 1998; 95: 3931–3936.
Koyama AH, Adachi H . Induction of apoptosis by herpes simplex virus type 1. J Gen Virol 1997; 78: 2909–2912.
Jerome KR, Tait JF, Koelle DM, Corey L . Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis. J Virol 1998; 72: 436–441.
Galvan V, Bradimarti R, Roizman B . Herpes simplex virus 1 blocks caspase-3-independent and caspase-dependent pathways to cell death. J Virol 1999; 73: 3219–3226.
Leopardi R, Roizman B . The herpes simplex virus major regulatory protein ICP4 blocks apoptosis induced by the virus or by hyperthermia. Proc Natl Acad Sci USA 1996; 93: 9583–9587.
Jerome KR, Fox R, Chen Z, Sears AE, Lee H, Corey L . Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol 1999; 73: 8950–8957.
Sawada T, Ho JJL, Chung YS . Stimulation of cellular motility by factor(s) released by SW1990 pancreatic cancer cells. Gastroenterology 1993; 104: A334.
Aoki K, Yoshida T, Matsumoto N . Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8: 1105–1113.
Hosono J, Narita T, Kimura N, Sato M, Nakashio T, Kasai Y . Involvement of adhesion molecules in metastasis of SW1990, human pancreatic cancer cells. J Surg Oncol 1998; 67: 77–84.
Rice SA, Lam V, Knipe DM . The acidic amino-terminal region of herpes simplex virus type 1 alpha protein ICP27 is required for an essential lytic function. J Virol 1993; 67: 1778–1787.
Carroll NM, Chiocca EA, Takahashi K, Tanabe KK . Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996; 224: 329–330.
Asano S, Honda T, Goshima F, Watanabe D, Miyake Y, Sugiura Y . US3 protein kinase of herpes simplex virus type 2 plays a role in protecting corneal epithelial cells from apoptosis in infected mice. J Gen Virol 1999; 80: 51–56.
Koyama AH, Akari H, Adachi A . Induction of apoptosis in Hep-2 cells by infection with herpes simplex virus type 2. Arch Virol 1998; 143: 2435–2441.
Antoni BA, Sabbatini P, Rabson AB, White E . Inhibition of apoptosis in human immunodeficiency virus-infected cells enhances virus production and facilitates persistent infection. J Virol 1995; 69: 2384–2392.
Chinnaiyan AM, Woffendin C, Dixit VM, Nabel GJ . The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. Nat Med 1997; 3: 333–337.
Sandstrom PA, Roberts B, Folks TM, Buttke TM . HIV gene expression enhances T cell susceptibility to hydrogen peroxide-induced apoptosis. AIDS Res Hum Retroviruses 1993; 9: 1107–1113.
Clem RJ, Fechheimer M, Miller LK . Protein prevention of apoptosis by a baculovirus gene during infection of insect cells. Science 1991; 29: 1388–1390.
Brun A, Rivas C, Esteban M, Escribano JM, Alonso C . African swine fever virus gene A179L, a viral homologue of bcl-2, protects cells from programmed cell death. Virology 1996; 225: 227–230.
Afonso CL, Neilan JG, Kutish GF, Rock DL . An African swine fever virus Bc1-2 homolog, 5-HL, suppresses apoptotic cell death. J Virol 1996; 70: 4858–4863.
Gooding LR . Virus proteins that counteract host immune defenses. Cell 1992; 71: 5–7 Review.
Sauthoff H, Heitner S, Rom WN, Hay JG . Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther 2000; 11: 379–388.
Boulakia CA, Chen G, Ng FW, Teodoro JG, Branton PE, Nicholson DW . Bcl-2 and adenovirus E1B 19kDA protein prevent E1A-induced processing of CPP32 and cleavage of poly (ADP-ribose) polymerase. Oncogene 1996; 12: 529–535.
Rao L, Perez D, White E . Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol 1996; 135: 1441–1455.
Hu MC, Hsu MT . Adenovirus E1B 19K protein is required for efficient DNA replication in U937 cells. Virology 1997; 227: 295–304.
Chiou SK, White E . Inhibition of ICE-like proteases inhibits apoptosis and increases virus production during adenovirus infection. Virology 1998; 244: 108–118.
Worgall S, Wolff G, Falck-Pedersen E, Crystal RG . Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37–44.
Yeung SN, Tufaro F . Replicating herpes simplex virus vectors for cancer gene therapy. Expert Opin Pharmacother 2000; 1: 623–631.
Varghese S, Rabkin SD . Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9: 967–978 Review.
Nakao A, Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T . Injection of herpes simplex virus HF10 in recurrent breast cancer. Ann Oncol 2004; 15: 988–989.
Takakuwa H, Goshima F, Nozawa N, Yoshikawa T, Kimata H, Nakao A . Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 2003; 148: 813–825.
Acknowledgements
This study was supported by the Grant-in-Aid for Scientific Research in Japan, No. 16390358. There is no financial conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kasuya, H., Nishiyama, Y., Nomoto, S. et al. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Cancer Gene Ther 14, 533–542 (2007). https://doi.org/10.1038/sj.cgt.7701049
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7701049
Keywords
This article is cited by
-
Designing herpes viruses as oncolytics
Molecular Therapy - Oncolytics (2015)
-
Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment
Cancer Immunology, Immunotherapy (2012)
-
Intelligent Design: Combination Therapy With Oncolytic Viruses
Molecular Therapy (2010)